Vanda Pharmaceuticals (VNDA) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.95 -0.83%
Revenue Growth %: +17.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +17.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $8.07 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Kroger meets earnings expectations, revenue tops estimates
- Smith & Wesson Brands (SWBI) Tops Q4 EPS by 15c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
